The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2015 | Recently approved drugs for the treatment of multiple myeloma
Gareth Morgan, MD, FRCP, FRCPath, PhD from the University of Arkansas for Medical Sciences, Arkansas, AR provides an overview of the drugs recently approved for the treatment multiple myeloma (MM), and for which the data has been presented at the American Society of Hematology (ASH) 2015 Annual Meeting, held in Orlando, FL. These include daratumumab, an anti-CD38 monoclonal antibody; ixazomib, the first oral proteasome inhibitor; and elotuzumab, a monoclonal antibody targeting signalling lymphocytic activation molecule F7 (SLAMF7).
